Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 4/20 | 0.36 |
| ▸ | NPY1R | P25929 | 3/20 | 0.36 |
| ▸ | NPY2R | P49146 | 3/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572314 | 1.00 | SPHK1 (0.43) | SPHK1SPHK2RENS1PR1S1PR3 | |
| SCHEMBL19820039 | 0.94 | SPHK1 (0.45) | SPHK1SPHK2RENS1PR1S1PR3 | |
| SCHEMBL20094895 | 0.88 | SPHK1 (0.40) | SPHK1SPHK2RENS1PR1S1PR3 | |
| SCHEMBL16572313 | 0.82 | SPHK1 (0.55) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL16627666 | 0.77 | SPHK1 (0.52) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL16627708 | 0.77 | SPHK1 (0.52) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL16572292 | 0.76 | SPHK1 (0.53) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL16572312 | 0.76 | SPHK1 (0.53) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL19366157 | 0.75 | NPY4R (0.33) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL19820059 | 0.72 | SPHK1 (0.50) | SPHK1SPHK2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260398-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150099764-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099764-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | SPHK1 339/4885SPHK2 337/4885REN 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.